Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1
Source : https://pubmed.ncbi.nlm.nih.gov/38710625/
Familial hypobetalipoproteinemia (FHBL) 1 is a rare genetic disorder with an autosomal codominant mode of inheritance and is caused by defects in the apolipoprotein (apo) B (APOB) gene that disable...
Familial hypobetalipoproteinemia 1 (FHBL1) is a rare genetic disorder impairing lipoprotein formation, causing hypolipidemia and fat malabsorption, leading to severe complications. Treatment is primarily palliative.
Share
Recent Treatment Strategies for Acute Pancreatitis
Source : https://pubmed.ncbi.nlm.nih.gov/38398290/
Acute pancreatitis (AP) is a leading gastrointestinal disease that causes hospitalization. Initial management in the first 72 h after the diagnosis of AP is pivotal, which can influence the clinical...
Acute pancreatitis (AP) management involves assessing severity, fluid resuscitation, pain control, and ERCP for gallstone cases. Hypertriglyceridemia management is crucial in AP treatment to prevent recurrence.
Share
Lipoprotein(a)'s Role in Atherosclerosis and Aortic Stenosis: A Contemporary Literature Review
Source : https://pubmed.ncbi.nlm.nih.gov/39044888/
Lipoprotein(a), or Lp(a), is a distinctive lipoprotein particle linked to various cardiovascular diseases, notably atherosclerosis and aortic stenosis. Much like plasminogen, Lp(a) hinders normal fibrinolysis, leading to increased thrombosis and...
Elevated Lp(a) levels are crucial in atherosclerosis and aortic stenosis, contributing to cardiovascular risks. Emerging therapies targeting Lp(a) offer hope for improved management and risk reduction.
Share
Do patients benefit from omega-3 fatty acids
Source : https://pubmed.ncbi.nlm.nih.gov/38252923/
Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV) health and elevated O3FA levels are associated with lower incident risk for CV disease (CVD.) Yet, treatment of at-risk patients...
EPA-only formulations demonstrate superior efficacy in reducing cardiovascular events compared to mixed O3FA or DHA formulations, likely due to unique mechanisms beyond lipid reduction.
Share
Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38399434/
Dyslipidaemia is a modifiable risk factor commonly associated with diabetes mellitus and prediabetes, with a major impact on the early development of atherosclerotic cardiovascular disease. Various studies have tried to...
Dyslipidaemia in diabetes and prediabetes contributes to early atherosclerosis. This review summarizes current lipid disorder treatments and guideline recommendations for managing dyslipidaemia with various pharmacologic options.
Share